These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8210255)

  • 1. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer].
    Sakata Y; Shimada Y; Yoshino M; Kambe M; Futatsuki K; Nakao I; Ogawa N; Wakui A; Taguchi T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1039-46. PubMed ID: 8210255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
    Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
    Taguchi T; Yoshida Y; Izuo M; Ishida T; Ogawa M; Nakao I; Tominaga T; Ohkawa T; Oguro M; Yoshida M
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):83-90. PubMed ID: 8291919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].
    Taguchi T; Tominaga T; Ogawa M; Ishida T; Morimoto K; Ogawa N
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1017-24. PubMed ID: 8210251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
    Shimada Y; Yoshino M; Wakui A; Nakao I; Futatsuki K; Sakata Y; Kambe M; Taguchi T; Ogawa N
    J Clin Oncol; 1993 May; 11(5):909-13. PubMed ID: 8487053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
    Fukuoka M; Niitani H; Suzuki A; Motomiya M; Hasegawa K; Nishiwaki Y; Kuriyama T; Ariyoshi Y; Negoro S; Masuda N
    J Clin Oncol; 1992 Jan; 10(1):16-20. PubMed ID: 1309380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].
    Negoro S; Fukuoka M; Niitani H; Suzuki A; Nakabayashi T; Kimura M; Motomiya M; Kurita Y; Hasegawa K; Kuriyama T
    Gan To Kagaku Ryoho; 1991 May; 18(6):1013-9. PubMed ID: 1851408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
    Ota K; Ohno R; Shirakawa S; Masaoka T; Okada K; Ohashi Y; Taguchi T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1047-55. PubMed ID: 8210256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
    Takeuchi S; Dobashi K; Fujimoto S; Tanaka K; Suzuki M; Terashima Y; Hasumi K; Akiya K; Negishi Y; Tamaya T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1681-9. PubMed ID: 1872624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
    Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
    Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer].
    Nishimura G; Satou T; Yoshimitsu Y; Kurosaka Y; Fujimura T; Sugiyama K; Kanno M; Yonemura Y; Miwa K; Miyazaki I
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):93-7. PubMed ID: 7826085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers].
    Takeuchi S; Takamizawa H; Takeda Y; Ohkawa T; Tamaya T; Noda K; Sugawa T; Sekiba K; Yakushiji M; Taguchi T
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):579-84. PubMed ID: 2012400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A phase I study of weekly administration of CPT-11 in lung cancer].
    Fukuoka M; Negoro S; Niitani H; Furue H; Hasegawa K; Hara Y; Hara N; Taguchi T
    Gan To Kagaku Ryoho; 1990 May; 17(5):993-7. PubMed ID: 2159268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study.
    Wagener DJ; Verdonk HE; Dirix LY; Catimel G; Siegenthaler P; Buitenhuis M; Mathieu-Boué A; Verweij J
    Ann Oncol; 1995 Feb; 6(2):129-32. PubMed ID: 7786820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
    Ohno R; Yoshida Y; Oguro M; Ogawa M; Sakai Y; Furue H; Ariyoshi Y; Saito H; Masaoka T; Kimura I
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):75-82. PubMed ID: 8291918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
    de Forni M; Bugat R; Chabot GG; Culine S; Extra JM; Gouyette A; Madelaine I; Marty ME; Mathieu-Boué A
    Cancer Res; 1994 Aug; 54(16):4347-54. PubMed ID: 8044782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An early phase II study of CPT-11 in primary lung cancer].
    Nakai H; Fukuoka M; Furuse K; Nakao I; Yoshimori K; Ogura T; Hara N; Sakata Y; Saito H; Hasegawa K
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):607-12. PubMed ID: 1849391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.